Matches in UGent Biblio for { <https://biblio.ugent.be/publication/3117905#aggregation> ?p ?o. }
Showing items 1 to 59 of
59
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B184756.
- aggregation creator B184757.
- aggregation creator B184758.
- aggregation creator B184759.
- aggregation creator B184760.
- aggregation creator B184761.
- aggregation creator B184762.
- aggregation creator B184763.
- aggregation creator B184764.
- aggregation creator B184765.
- aggregation creator B184766.
- aggregation creator B184767.
- aggregation creator B184768.
- aggregation creator B184769.
- aggregation creator B184770.
- aggregation creator B184771.
- aggregation creator B184772.
- aggregation creator B184773.
- aggregation creator B184774.
- aggregation creator B184775.
- aggregation creator B184776.
- aggregation creator B184777.
- aggregation creator B184778.
- aggregation creator B184779.
- aggregation creator B184780.
- aggregation creator B184781.
- aggregation creator B184782.
- aggregation creator person.
- aggregation date "2013".
- aggregation format "application/pdf".
- aggregation hasFormat 3117905.bibtex.
- aggregation hasFormat 3117905.csv.
- aggregation hasFormat 3117905.dc.
- aggregation hasFormat 3117905.didl.
- aggregation hasFormat 3117905.doc.
- aggregation hasFormat 3117905.json.
- aggregation hasFormat 3117905.mets.
- aggregation hasFormat 3117905.mods.
- aggregation hasFormat 3117905.rdf.
- aggregation hasFormat 3117905.ris.
- aggregation hasFormat 3117905.txt.
- aggregation hasFormat 3117905.xls.
- aggregation hasFormat 3117905.yaml.
- aggregation isPartOf urn:issn:1470-2045.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study".
- aggregation abstract "Background : Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma. Methods : In this completed, multicentre, randomised, placebo-controlled, double-blind, phase 2 study, we enrolled patients with advanced hepatocellular carcinoma and Child-Pugh A cirrhosis who had progressed on or were unable to tolerate first-line systemic therapy. We randomly allocated patients 2:1 to receive tivantinib (360 mg twice-daily) or placebo until disease progression. The tivantinib dose was amended to 240 mg twice-daily because of high incidence of treatment-emergent grade 3 or worse neutropenia. Randomisation was done centrally by an interactive voice-response system, stratified by Eastern Cooperative Oncology Group performance status and vascular invasion. The primary endpoint was time to progression, according to independent radiological review in the intention-to-treat population. We assessed tumour samples for MET expression with immunohistochemistry (high expression was regarded as >= 2+ in >= 50% of tumour cells). This study is registered with ClinicalTrials.gov, number NCT00988741. Findings : 71 patients were randomly assigned to receive tivantinib (38 at 360 mg twice-daily and 33 at 240 mg twice-daily); 36 patients were randomly assigned to receive placebo. At the time of analysis, 46 (65%) patients in the tivantinib group and 26 (72%) of those in the placebo group had progressive disease. Time to progression was longer for patients treated with tivantinib (1.6 months [95% CI 1.4-2.8]) than placebo (1.4 months [1.4-1.5]; hazard ratio [HR] 0.64, 90% CI 0.43-0.94; p=0.04). For patients with MET-high tumours, median time to progression was longer with tivantinib than for those on placebo (2.7 months [95% CI 1.4-8.5] for 22 MET-high patients on tivantinib vs 1.4 months [1.4-1.6] for 15 MET-high patients on placebo; HR 0.43, 95% CI 0.19-0.97; p=0.03). The most common grade 3 or worse adverse events in the tivantinib group were neutropenia (ten patients [14%] vs none in the placebo group) and anaemia (eight [11%] vs none in the placebo group). Eight patients (21%) in the tivantinib 360 mg group had grade 3 or worse neutropenia compared with two (6%) patients in the 240 mg group. Four deaths related to tivantinib occurred from severe neutropenia. 24 (34%) patients in the tivantinib group and 14 (39%) patients in the placebo group had serious adverse events. Interpretation : Tivantinib could provide an option for second-line treatment of patients with advanced hepatocellular carcinoma and well-compensated liver cirrhosis, particularly for patients with MET-high tumours. Confirmation in a phase 3 trial is needed, with a starting dose of tivantinib 240 mg twice-daily.".
- aggregation authorList BK442403.
- aggregation endPage "63".
- aggregation issue "1".
- aggregation startPage "55".
- aggregation volume "14".
- aggregation aggregates 3117939.
- aggregation isDescribedBy 3117905.
- aggregation similarTo S1470-2045(12)70490-4.
- aggregation similarTo LU-3117905.